Isoray, Inc. (ISR) Bundle
A Brief History of Isoray, Inc. (ISR)
Foundation and Early Years
Foundation and Early Years
Isoray, Inc. was founded in 2004, headquartered in Richland, Washington. The company focuses on innovative medical technologies and specializes in the development of medical isotopes used for cancer treatment.
Product Development
In 2005, Isoray launched its flagship product, Cesium-131, a radioactive isotope used in brachytherapy, specifically targeting prostate cancer. This product aimed to provide improved treatment options compared to traditional therapies using iodine-125.
Regulatory Approvals
In 2010, the U.S. Food and Drug Administration (FDA) granted Isoray approval for Cesium-131 for use in a variety of cancers, including prostate, brain, and lung. This marked a significant milestone for the company, enabling it to expand its market reach.
Financial Milestones
As of the end of the fiscal year 2022, Isoray reported revenues of $12.1 million, a notable increase compared to $9.8 million in 2021. The company has shown a consistent growth trend in revenue through its expanding product line and market acceptance.
Strategic Partnerships
In 2017, Isoray entered into a partnership with American Medical Systems to co-develop and market new brachytherapy products, further enhancing its technological offerings.
Market Expansion
In 2019, Isoray expanded its market presence internationally, specifically in Europe and Asia. The company also launched its product in various U.S. clinics, increasing treatment accessibility for patients.
Recent Developments
By 2023, Isoray achieved a significant milestone with the announcement of a new product launch, GliaSite, targeting brain cancer treatments specifically designed for the glioblastoma multiforme patient population.
Financial Performance Table
| Year | Revenue (in millions) | Net Loss (in millions) | Stock Price (as of December 2022) |
|---|---|---|---|
| 2020 | $8.5 | ($3.1) | $0.80 |
| 2021 | $9.8 | ($2.5) | $1.15 |
| 2022 | $12.1 | ($1.8) | $1.50 |
| 2023 | Projected at $15.0 | Projected loss at ($1.2) | $1.75 |
Stock Performance
As of October 2023, Isoray's stock price is approximately $1.75. The company has experienced fluctuations in stock price over the years, reflecting broader market trends and investor sentiment.
Future Outlook
The company aims to reach revenues of $20 million by fiscal year 2024, focusing on expanding its product offerings and strategic partnerships in cancer treatment technology.
A Who Owns Isoray, Inc. (ISR)
Ownership Structure
Ownership Structure
As of the latest available data, Isoray, Inc. (ISR) has a diverse ownership structure, comprising institutional investors, individual shareholders, and insiders.
| Owner Type | Ownership Percentage | Number of Shares | Value (USD) |
|---|---|---|---|
| Institutional Investors | 28.5% | 11,000,000 | 11,550,000 |
| Insider Ownership | 5.2% | 2,000,000 | 2,100,000 |
| Retail Investors | 66.3% | 26,000,000 | 27,300,000 |
Institutional Investors
Institutional investors play a significant role in Isoray's ownership, with major firms holding substantial shares.
| Institution | Shares Held | Ownership Percentage | Value (USD) |
|---|---|---|---|
| The Vanguard Group, Inc. | 4,200,000 | 10.5% | 4,410,000 |
| BlackRock, Inc. | 3,500,000 | 8.8% | 3,675,000 |
| State Street Global Advisors | 2,300,000 | 5.8% | 2,415,000 |
| Goldman Sachs Group, Inc. | 1,000,000 | 2.5% | 1,050,000 |
Insider Ownership
Insiders also have a vested interest in the company, reflecting confidence in the future of Isoray.
| Name | Title | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Thomas J. LaVoy | CEO | 1,000,000 | 2.5% |
| Mark A. S. Brenner | CFO | 800,000 | 2.0% |
| R. Andrew Cryer | Board Member | 200,000 | 0.5% |
Share Performance
As of October 2023, Isoray shares are valued at approximately $1.05 per share, reflecting a market capitalization of around $41 million.
| Metric | Value |
|---|---|
| Current Share Price (USD) | 1.05 |
| Market Capitalization (USD) | 41,000,000 |
| 52-Week High (USD) | 1.25 |
| 52-Week Low (USD) | 0.75 |
Recent Developments
Recent announcements and developments impact shareholder sentiment and stock performance.
- Partnership with a leading healthcare provider for expanded product offerings.
- New product launch projected to increase revenue by 15% within the next fiscal year.
- Shareholder meeting scheduled for Q1 2024 to discuss growth strategies.
Isoray, Inc. (ISR) Mission Statement
Isoray, Inc. is dedicated to improving the lives of cancer patients through innovative treatments that utilize its proprietary technology and radioactive seed therapy. The company's mission statement underscores its commitment to addressing the unmet needs in cancer treatment, enhancing patient care, and pushing the boundaries of scientific research.
Core Values
- Innovation: Continuous development of cutting-edge technology for cancer treatment.
- Patient Focus: Prioritizing the needs and well-being of patients undergoing treatment.
- Integrity: Upholding the highest ethical standards in all aspects of the business.
- Collaboration: Partnering with healthcare providers to improve patient outcomes.
- Quality: Ensuring all products and services meet the highest quality standards.
Strategic Goals
- To expand the clinical applications of its brachytherapy technology in various cancer treatments.
- To increase market penetration and enhance distribution channels in both domestic and international markets.
- To invest in research and development to optimize treatment efficacy and safety.
- To foster educational initiatives that promote awareness and understanding of its treatments among healthcare professionals.
Financial Overview
As of the last fiscal report, Isoray, Inc. reported a revenue of $12.5 million for the fiscal year ending June 30, 2023, representing an increase of 15% compared to the previous year. The gross profit margin stood at 80%, highlighting the company's efficiency in managing production costs.
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $12.5 million | $10.9 million |
| Gross Profit Margin | 80% | 75% |
| Net Loss | ($3.4 million) | ($3.1 million) |
| Cash and Cash Equivalents | $7.1 million | $6.3 million |
| Market Capitalization | $60 million | $50 million |
Investment and Research Initiatives
Isoray has allocated approximately $3 million for research and development in the current fiscal year, targeting advancements in its lead product, Cesium-131 seeds, used in treating prostate cancer and other malignancies.
Recent Developments
In September 2023, Isoray received FDA approval for a new clinical trial focusing on the treatment of head and neck cancers using its proprietary technology.
Community Engagement
The company actively participates in cancer awareness programs, contributing over $150,000 annually to support initiatives that educate the public about cancer treatment options.
How Isoray, Inc. (ISR) Works
Company Overview
Company Overview
Isoray, Inc. specializes in innovative cancer therapies using brachytherapy. The company is primarily known for its patented radioactive seed technology, which is used in the treatment of various cancer types, particularly prostate cancer.
Market Segment
Isoray operates within the medical device industry, particularly focusing on oncology treatment. The global brachytherapy market was valued at approximately $4 billion in 2021 and is projected to grow at a CAGR of around 6.2% from 2022 to 2030.
Financial Performance
As of the fiscal year ending June 30, 2023, Isoray reported the following financial metrics:
| Financial Metric | Amount ($) |
|---|---|
| Total Revenue | $8.1 million |
| Net Income | ($1.2 million) |
| Cash and Cash Equivalents | $4.5 million |
| Market Capitalization | $70 million |
| Debt to Equity Ratio | 0.07 |
Product Line
Isoray's product line includes:
- Seed brachytherapy products
- Cesium-131 seeds
- LDR (Low Dose Rate) and HDR (High Dose Rate) brachytherapy
- Radiation treatment planning software
Research and Development
In 2023, Isoray spent approximately $1.5 million on research and development activities, focusing on enhancing treatment protocols and expanding their product offerings.
Partnerships and Collaborations
Isoray has established partnerships with numerous healthcare institutions. Recent collaborations include joint research agreements with:
- Johns Hopkins University
- Cleveland Clinic
- Mayo Clinic
Sales and Distribution
The company operates through various channels:
- Direct sales to hospitals and clinics
- Distributors across the United States and internationally
- Online platforms for educational resources and product information
Competitive Landscape
Key competitors in the brachytherapy market include:
- Boston Scientific
- Varian Medical Systems
- Teleflex Incorporated
Regulatory Compliance
Isoray maintains compliance with FDA regulations and holds the following certifications:
- ISO 13485 certification
- FDA 510(k) clearances for its products
Future Outlook
The company is targeting a revenue growth of 15% for the upcoming fiscal year, driven by expanding its market reach and enhancing product utilization in existing healthcare networks.
How Isoray, Inc. (ISR) Makes Money
Revenue Streams
Isoray, Inc. (ISR) primarily generates revenue through the sale of its innovative brachytherapy products, which are used in cancer treatment. The company's flagship product is the Cesium-131 seed, which is used for treating various types of cancer including prostate cancer.
Product Sales
In FY 2023, Isoray reported total revenues of $12.1 million, representing a growth of 40% from $8.6 million in FY 2022. This increase is attributed to a rise in demand for its Cesium-131 products.
| Year | Revenue (in millions) | Percentage Growth |
|---|---|---|
| 2021 | $6.5 | - |
| 2022 | $8.6 | 32% |
| 2023 | $12.1 | 40% |
Contracts and Partnerships
Isoray has established partnerships with various hospitals and cancer treatment centers, enhancing its distribution networks. As of 2023, Isoray has over 1,000 clinical sites using its products. These partnerships contribute significantly to sales volume and market penetration.
Research and Development (R&D) Investments
The company invests heavily in R&D to develop new applications of Cesium-131 and improve treatment efficacy. In FY 2023, R&D expenses were approximately $2.5 million, aimed at expanding the product pipeline and enhancing existing technologies.
Market Expansion
Isoray is focusing on expanding its reach into international markets. In FY 2023, around 15% of its revenue was generated from international sales, particularly in Europe and Asia.
| Region | Revenue Contribution (in millions) | Percentage of Total Revenue |
|---|---|---|
| USA | $10.3 | 85% |
| Europe | $1.5 | 12.4% |
| Asia | $0.3 | 2.5% |
Market Positioning
Isoray holds a competitive position in the brachytherapy market, where it competes with other radionuclide therapies. As of 2023, Isoray captured 25% of the U.S. prostate brachytherapy market.
Cost Management
Efficient cost management strategies have allowed Isoray to maintain healthy margins. In FY 2023, the cost of goods sold (COGS) was approximately $5.0 million, resulting in a gross profit of $7.1 million, yielding a gross margin of 58.8%.
Outlook and Future Earnings
Analysts forecast steady revenue growth for Isoray, projecting a revenue target of $20 million by FY 2025, driven by increasing adoption of its therapies and expanding market presence.
Isoray, Inc. (ISR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support